Study suggests antipsychotic drugs during pregnancy linked to increased risk of gestational diabetes

July 2, 2012

A study that examined maternal use of antipsychotic drugs during pregnancy suggests that these medications may be linked to an increased risk of gestational diabetes, according to a report in the July issue of Archives of General Psychiatry.

Severe , such as schizophrenia and , are usually treated with continuous , "however, the evidence concerning use of antipsychotics during pregnancy is generally lacking or weak," the authors write in the study background.

Robert Bodén. M.D., Ph.D., of the Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, and Uppsala University, Uppsala, Sweden, and colleagues used Swedish national health registers for a population-based study that also examined the effects of antipsychotic drugs during pregnancy on fetal growth.

Women who gave birth in Sweden from July 2005 through December 2009, were grouped by filled prescriptions for: (1) the antipsychotics olanzapine and/or clozapine (n=169); (2) other antipsychotics (n=338); or (3) no antipsychotics (n=357,696).

"Gestational diabetes was more than twice as common in mothers who used antipsychotics (seven mothers [4.1 percent] for group 1 and 15 [4.4 percent] for group 2) than in the total population of pregnant women (5,970 [1.7 percent])," according to the study results. The risk increase with olanzapine and/or clozapine was of similar magnitude but not statistical significance, the results indicate.

Women using antipsychotics also had an increased risk of giving birth to a small for gestational age (SGA) infant but, after adjusting for maternal factors, the risk was no longer statistically significant, according to the results.

"In conclusion, maternal use of antipsychotics during pregnancy, regardless of the drug group, is associated with an increased risk of gestational diabetes. The increased risk of giving birth to an SGA infant observed among women treated with antipsychotics during pregnancy is probably an effect of confounding factors, such as smoking," the authors comment.

The results also indicate there were no increased risks of being large for gestational age (LGA) for birth weight or birth length after exposure to olanzapine and/or clozapine, but the risk increased for head circumference.

"Pregnant women treated with should be closely monitored for and deviating fetal growth," the researchers conclude.

Explore further: Maternal use of SSRIs associated with fewer depressive symptoms, delayed fetal head growth

More information: Arch Gen Psychiatry. 2012;69[7]:715-721.

Related Stories

Recommended for you

Serious research into what makes us laugh

November 24, 2015

More complex jokes tend to be funnier but only up to a point, Oxford researchers have found. Jokes that are too complicated tend to lose the audience.

Psychologists dispute continuum theory of sexual orientation

November 19, 2015

Washington State University researchers have established a categorical distinction between people who are heterosexual and those who are not. By analyzing the reported sexual behavior, identity and attraction of more than ...

Babies have logical reasoning before age one, study finds

November 18, 2015

Human infants are capable of deductive problem solving as early as 10 months of age, a new study by psychologists at Emory University and Bucknell finds. The journal Developmental Science is publishing the research, showing ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.